Stockscreener 앱 받기
8.91
2.94%
-0.27
시장 영업 전:
9.35
0.44
+4.94%
Artiva Biotherapeutics Inc 주식(ARTV)의 최신 뉴스
Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK - RTTNews
Thursday’s insider buys and sells: Healthcare and tech in focus - Investing.com UK
Thursday’s insider buys and sells: Healthcare and tech in focus By Investing.com - Investing.com UK
Major Insider Move Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com - Investing.com Nigeria
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock - Investing.com UK
ARTV Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Weakness Phase - newsline.com
ARTV Q1 2026 Earnings: Surprise EPS Miss Amid Pre-Revenue Stage, Stock Gains 6.91%Net Income Trends - The League of Women Voters of Texas
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $41 - Moomoo
ARTV: AlloNK demonstrates strong efficacy and safety in refractory RA, advancing to pivotal phase III - TradingView
ARTV: AlloNK plus rituximab achieves 71% ACR50 at 6 months in refractory RA with strong safety - TradingView
FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis - Traders Union
Artiva Biotherapeutics stock surges on FDA RMAT designation By Investing.com - Investing.com Canada
Artiva Biotherapeutics stock surges on FDA RMAT designation - Investing.com
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today - The Manila Times
AlloNK shows strong clinical results in refractory rheumatoid arthritis; FDA grants RMAT designation - Pluang
Artiva Biotherapeutics Highlights Promising AlloNK Data for B-cell Depletion in Autoimmune Diseases at EULAR 2026 - Quiver Quantitative
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in ... - Caledonian Record
Artiva Biotherapeutics Highlights AlloNK Data Presented At EULAR 2026 And Receives FDA RMAT Designation In Refractory Rheumatoid Arthritis - marketscreener.com
Artiva Biotherapeutics announces positive AlloNK data - grafa.com
ARTV: Pivotal trial in refractory RA to start in late 2024, with durable efficacy and strong financial runway - TradingView
Artiva Stock on Watch with EULAR Data and Jefferies in Play - Bez Kabli
Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis - Traders Union
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Artiva rises after mid-stage trial data for lead asset in rheumatoid arthritis - MSN
Artiva Biotherapeutics (ARTV) Rises 1.84% as Shares Approach ResistanceEnding Diagonal - newsline.com
Major Investor Makes Bold Move Into Artiva Biotherapeutics Stock - TipRanks
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event - Traders Union
Cantor Fitzgerald Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating - Investing.com UK
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating By Investing.com - Investing.com Nigeria
The Bear Cave #327by Edwin Dorsey - The Bear Cave | Edwin Dorsey
ARTV Stock Price, Quote & Chart | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock By Investing.com - Investing.com Nigeria
As Griffith retires, Dittrich returns to Amgen, takes CFO role - BioCentury
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock By Investing.com - Investing.com Nigeria
Artiva names Diego Miralles as president and head of R&D - The Pharma Letter
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock - Investing.com India
Artiva Biotherapeutics, Inc. Appoints New Principal Financial Officer and President in May 2026 - Minichart
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock - Investing.com India
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock By Investing.com - Investing.com India
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock - Investing.com India
1.27%
1.43%
자본화:
|
볼륨(24시간):